• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Recurrent ventricular fibrillation with different tyrosine kinase inhibitors for chronic myeloid leukemia.

作者信息

Prashar Abhisheik, Ilsar Rahn, Roncolato Fernando, Hopkins Andrew

机构信息

Department of Cardiology, St George Hospital, Sydney, Australia.

University of New South Wales, Sydney, Australia.

出版信息

HeartRhythm Case Rep. 2020 Jul 29;6(10):770-773. doi: 10.1016/j.hrcr.2020.07.016. eCollection 2020 Oct.

DOI:10.1016/j.hrcr.2020.07.016
PMID:33101952
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7573469/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/745b/7573469/419ccf0b367b/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/745b/7573469/1441326553b7/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/745b/7573469/50a548bac03a/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/745b/7573469/419ccf0b367b/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/745b/7573469/1441326553b7/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/745b/7573469/50a548bac03a/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/745b/7573469/419ccf0b367b/gr3.jpg

相似文献

1
Recurrent ventricular fibrillation with different tyrosine kinase inhibitors for chronic myeloid leukemia.不同酪氨酸激酶抑制剂治疗慢性髓性白血病时的复发性心室颤动
HeartRhythm Case Rep. 2020 Jul 29;6(10):770-773. doi: 10.1016/j.hrcr.2020.07.016. eCollection 2020 Oct.
2
Management of sudden cardiac death in cardiac sarcoidosis using the wearable cardioverter defibrillator.使用可穿戴式除颤器管理心脏结节病中的心脏性猝死。
PLoS One. 2018 Mar 22;13(3):e0194496. doi: 10.1371/journal.pone.0194496. eCollection 2018.
3
[Sudden cardiac death in the youth. Is the new subcutaneous implantable cardioverter defibrillator S-ICD an alternative solution?].[青年心脏性猝死。新型皮下植入式心律转复除颤器S-ICD是一种替代解决方案吗？]
Ann Cardiol Angeiol (Paris). 2015 Feb;64(1):27-31. doi: 10.1016/j.ancard.2014.08.018. Epub 2014 Sep 18.
4
Ventricular fibrillation in patients without significant structural heart disease: a multicenter experience with implantable cardioverter-defibrillator therapy.无明显结构性心脏病患者的心室颤动：植入式心脏复律除颤器治疗的多中心经验
J Am Coll Cardiol. 1993 May;21(6):1406-12. doi: 10.1016/0735-1097(93)90317-t.
5
Subcutaneous implantable cardioverter defibrillator indication in prevention of sudden cardiac death in difficult clinical situations: A French expert position paper.皮下植入式心律转复除颤器在困难临床情况下预防心源性猝死的适应证：法国专家立场文件。
Arch Cardiovasc Dis. 2020 May;113(5):359-366. doi: 10.1016/j.acvd.2020.03.011. Epub 2020 Apr 22.
6
Impact of the implantable cardioverter-defibrillator on rehospitalizations.植入式心脏复律除颤器对再次住院的影响。
Eur Heart J. 1996 Oct;17(10):1565-71. doi: 10.1093/oxfordjournals.eurheartj.a014722.
7
Subcutaneous Implantable Cardioverter Defibrillator: Early Experience.皮下植入式心律转复除颤器：早期经验。
Braz J Cardiovasc Surg. 2017 Nov-Dec;32(6):498-502. doi: 10.21470/1678-9741-2017-0082.
8
[Long-term outcome of pharmacological and nonpharmacological treatment for ventricular arrhythmias].[室性心律失常的药物和非药物治疗的长期结果]
J Cardiol. 2000 Mar;35 Suppl 1:75-84.
9
The subcutaneous implantable cardioverter and defibrillator: advantages, limitations and future directions.皮下植入式心脏复律除颤器：优势、局限性及未来方向。
Expert Rev Cardiovasc Ther. 2015;13(9):989-99. doi: 10.1586/14779072.2015.1071189.
10
Implantable cardioverter-defibrillator: present and future indications.植入式心脏复律除颤器：当前及未来的适应症
Arch Mal Coeur Vaiss. 1996 Feb;89 Spec No 1:141-7.

引用本文的文献

1
Comparative arrhythmia patterns among patients on tyrosine kinase inhibitors.酪氨酸激酶抑制剂治疗患者的心律失常模式比较。
J Interv Card Electrophysiol. 2024 Jan;67(1):111-118. doi: 10.1007/s10840-023-01575-z. Epub 2023 May 31.
2
Tyrosine kinase inhibitor-associated ventricular arrhythmias: a case series and review of literature.酪氨酸激酶抑制剂相关性室性心律失常：病例系列及文献复习。
J Interv Card Electrophysiol. 2023 Aug;66(5):1165-1175. doi: 10.1007/s10840-022-01400-z. Epub 2022 Nov 21.

本文引用的文献

1
Ventricular tachycardia in the absence of structural heart disease.无结构性心脏病的室性心动过速。
Heart. 2019 Apr;105(8):645-656. doi: 10.1136/heartjnl-2017-311590. Epub 2018 Dec 12.
2
Coronary artery spasms due to tyrosine kinase inhibitors used in chronic myeloid leukemia.慢性髓性白血病中酪氨酸激酶抑制剂所致的冠状动脉痉挛。
Neth J Med. 2018 Sep;76(7):330-335.
3
Ibrutinib, an Approved Tyrosine Kinase Inhibitor as a Potential Cause of Recurrent Polymorphic Ventricular Tachycardia.依鲁替尼，一种已获批的酪氨酸激酶抑制剂，可能是复发性多形性室性心动过速的潜在病因。
JACC Clin Electrophysiol. 2016 Dec;2(7):847-849. doi: 10.1016/j.jacep.2016.07.004. Epub 2016 Sep 14.
4
Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing.心血管、肺部和代谢毒性并发症慢性髓性白血病酪氨酸激酶抑制剂治疗：监测、检测和管理策略。
Blood Rev. 2018 Jul;32(4):289-299. doi: 10.1016/j.blre.2018.01.004. Epub 2018 Feb 3.
5
Reversible ventricular arrythmia induced by dasatinib.达沙替尼诱发的可逆性室性心律失常。
Clin Case Rep. 2013 Oct;1(1):20-5. doi: 10.1002/ccr3.5. Epub 2013 Jul 31.
6
Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).酪氨酸激酶抑制剂的心血管安全性：特别关注心脏复极（QT 间期）。
Drug Saf. 2013 May;36(5):295-316. doi: 10.1007/s40264-013-0047-5.